Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies : A Multi-Centre Study
Sancho-Saldaña, Agustín (Institut de Recerca Biomèdica de Lleida)
Gil Sánchez, Anna (Institut de Recerca Biomèdica de Lleida)
González-Mingot, Cristina (Institut de Recerca Biomèdica de Lleida)
Peralta, Silvia (Multiple Sclerosis Foundation from Lleida)
Solana, Maria José (Institut de Recerca Biomèdica de Lleida)
Torres, Pascual (Institut de Recerca Biomèdica de Lleida)
Juanes, Alba (Institut de Recerca Biomèdica de Lleida)
Quibus, Laura (Institut de Recerca Biomèdica de Lleida)
Ruiz, Emilio (Institut de Recerca Biomèdica de Lleida)
Sanpedro, Eduardo (Institut de Recerca Biomèdica de Lleida)
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Presas Rodríguez, Sílvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
García Rubio, Sebatián (Hospital Universitario Miguel Servet (Saragossa))
Baron, Beatriz Pardiñas (Hospital Universitario Miguel Servet (Saragossa))
Ramió-Torrentà, Lluís (Universitat de Girona)
Sotoca Fernández, Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
González-Suárez, Inés (Hospital Álvaro Cunqueiro (Vigo))
Eichau Madueño, Sara (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Prieto, Jose Maria (Fundación Instituto de Investigación Sanitaria de Santiago (IDIS))
Blasco Quilez, Maria Rosario (Clínica Puerta de Hierro)
Sabín-Muñoz, Julia (Universidad Autónoma de Madrid)
Sánchez-López, Antonio José (Puerta de Hierro-Segovia de Arana Health Research Institute)
Llorens Calatayud, Gloria (Hospital Mateu Orfila)
Calles, Carmen (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Perez-Sempere, Angel (Universidad Miguel Hernández de Elche)
Garces, Moises (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Carmona, Olga (Fundació Salut Empordà)
Moral, Ester (Hospital de Sant Joan Despí Moisès Broggi)
Hervás, José Vicente (Hospital de Sant Joan Despí Moisès Broggi)
Blanco, Yolanda (Hospital Clínic i Provincial de Barcelona)
Sola-Valls, Nuria (Hospital Universitari Sant Joan de Reus (Tarragona))
Téllez Lara, Nieves (Hospital Clínico Universitario de Valladolid)
Forero, Lucía (Hospital Universitario Puerta del Mar (Cadis, Andalusia))
Brieva Ruiz, Luis (Institut de Recerca Biomèdica de Lleida)

Fecha:	2023
Resumen:	Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16. 9% vs. 8. 4%; p 0. 003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8. 5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.
Ayudas:	Instituto de Salud Carlos III COV20/00948
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Multiple Sclerosis ; COVID-19 ; SARS-CoV-2 ; DMT ; Seroprevalence
Publicado en:	Journal of clinical medicine, Vol. 12, Num. 23 (November 2023) , art. 7243, ISSN 2077-0383

DOI: 10.3390/jcm12237243
PMID: 38068295

13 p, 2.4 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados